

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 2

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

SUS  
H,  
57. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

58. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

59. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

92  
60. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

61. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

62. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

63. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 3

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

503  
H1 } 64. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

65. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

66. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

92 67. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

68. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

69. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

70. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

71. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

72. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

93 79. An isolated cell that produces the antibody of claim 45.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 4

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

SUB  
14. > 90. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

91. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

92. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

94 93. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

94. A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

95. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

96. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

97. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

Applicant : Takuya Tamatani et al.  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 5

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

94 SUB  
H1  
98. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

99. A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

---